Patents by Inventor Uwe Grether

Uwe Grether has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL PYRAZOL DERIVATIVES
    Publication number: 20150376192
    Abstract: The invention relates to a compound of formula (I) wherein A1 to A3 and R1 to R3 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: September 3, 2015
    Publication date: December 31, 2015
    Applicant: Hoffmann-La Roche Inc.
    Inventors: UWE GRETHER, ATSUSHI KIMBARA, NETTEKOVEN MATTHIAS, RICKLIN FABIENNE, ROEVER STEPHAN, MARK ROGERS-EVANS, TANJA SCHULZ-GASCH
  • PYRIDINE-2-AMIDES USEFUL AS CB2 AGONISTS
    Publication number: 20150344429
    Abstract: The invention relates to a compound of formula (I) wherein R1 to R4 are defined as in the description and in the claims. The compound of formula (I) is a CB2 agonist and can be used as an active ingredient in a medicament.
    Type: Application
    Filed: December 4, 2013
    Publication date: December 3, 2015
    Inventors: Uwe GRETHER, Atsushi KIMBARA, Matthias NETTEKOVEN, Fabienne RICKLIN, Stephan ROEVER, Mark ROGERS-EVANS, Didier ROMBACH, Tanja SCHULZ-GASCH, Matthias WESTPHAL
  • NOVEL PYRIDINE DERIVATIVES
    Publication number: 20150307452
    Abstract: The invention relates to a compound of formula (I) wherein R1 to R3 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: December 2, 2013
    Publication date: October 29, 2015
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Beat FREI, Luca GOBBI, Uwe GRETHER, Atsushi KIMBARA, Matthias NETTEKOVEN, Stephan ROEVER, Mark ROGERS-EVANS, Tanja SCHULZ-GASCH
  • NOVEL PYRAZINE DERIVATIVES AS CB2 RECEPTOR AGONISTS
    Publication number: 20150299220
    Abstract: The invention relates to a compound of formula (I) wherein R1 to R4 are defined as in the description and in the claims. The compound of formula (I) is a CB2 receptor agonist for use in the treatment of several disorders, such as pain, atherosclerosis and glaucoma.
    Type: Application
    Filed: December 4, 2013
    Publication date: October 22, 2015
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Baledi DHURWASULU, Uwe GRETHER, Matthias NETTEKOVEN, Stephan ROEVER, Mark ROGERS-EVANS, Tanja SCHULZ-GASCH
  • PYRIDINE-2-AMIDES USEFUL AS CB2 AGONISTS
    Publication number: 20150299165
    Abstract: The invention relates to CB2 agonists of formula (I) wherein R1 to R4 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: December 4, 2013
    Publication date: October 22, 2015
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Stefanie BENDELS, Uwe GRETHER, Atsushi KIMBARA, Matthias NETTEKOVEN, Stephan ROEVER, Mark ROGERS-EVANS, Ernst SCHAFFTER, Tanja SCHULZ-GASCH
  • Adamantyl derivatives as cannabinoid receptor 2 agonists
    Patent number: 9090615
    Abstract: The invention relates to a compound of formula (I) wherein A1, R1 and R2 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Grant
    Filed: December 22, 2014
    Date of Patent: July 28, 2015
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Atsushi Kimbara, Uwe Grether, Matthias Nettekoven, Bernd Puellmann, Mark Rogers-Evans, Tanja Schulz-Gasch
  • [1,2,3]triazolo[4,5-D]pyrimidine derivatives
    Patent number: 9067943
    Abstract: The invention relates to a compound of formula (I) wherein A and R1 to R3 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Grant
    Filed: November 19, 2012
    Date of Patent: June 30, 2015
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Caterina Bissantz, Uwe Grether, Atsushi Kimbara, Matthias Nettekoven, Stephan Roever, Mark Rogers-Evans
  • [1,2,3]triazolo[4,5-D]pyrimidine derivatives
    Patent number: 9056866
    Abstract: The invention relates to a compound of formula (I) wherein A, R1 and R2 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Grant
    Filed: April 11, 2014
    Date of Patent: June 16, 2015
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Jean-Michel Adam, Caterina Bissantz, Uwe Grether, Atsushi Kimbara, Matthias Nettekoven, Stephan Roever, Mark Rogers-Evans
  • NOVEL ADAMANTYL DERIVATIVES AS CANNABINOID RECEPTOR 2 AGONISTS
    Publication number: 20150111886
    Abstract: The invention relates to a compound of formula (I) wherein A1, R1 and R2 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: December 22, 2014
    Publication date: April 23, 2015
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Atsushi Kimbara, Uwe Grether, Matthias Nettekoven, Bernd Puellmann, Mark Rogers-Evans, Tanja Schulz-Gasch
  • NOVEL [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES
    Publication number: 20140288046
    Abstract: The invention relates to a compound of formula (I) wherein A, R1 and R2 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: April 11, 2014
    Publication date: September 25, 2014
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Jean-Michel Adam, Caterina Bissantz, Uwe Grether, Atsushi Kimbara, Matthias Nettekoven, Stephan Roever, Mark Rogers-Evans
  • [1,2,3]triazolo[4,5-D]pyrimidine derivatives
    Patent number: 8741906
    Abstract: The invention relates to a compound of formula (I) wherein A, R1 and R2 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Grant
    Filed: November 6, 2012
    Date of Patent: June 3, 2014
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Jean-Michel Adam, Caterina Bissantz, Uwe Grether, Atsushi Kimbara, Matthias Nettekoven, Stephan Roever, Mark Rogers-Evans
  • 3-pyridine carboxylic acid hydrazides
    Patent number: 8648099
    Abstract: The present invention relates to compounds of formula I, wherein R1 to R5 are defined in the description and claims, and to pharmaceutically acceptable salts thereof. The present invention relates also to the manufacture of said compounds, pharmaceutical compositions containing them and methods for the treatment and/or prophylaxis of diseases which can be treated with HDL-cholesterol raising agents, such as dyslipidemia, atherosclerosis and cardiovascular diseases.
    Type: Grant
    Filed: September 11, 2012
    Date of Patent: February 11, 2014
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Uwe Grether, Paul Hebeisen, Peter Mohr, Fabienne Ricklin, Stephan Roever
  • 5-cycloalkyl- or 5-heterocyclyl-nicotinamides
    Patent number: 8629166
    Abstract: The present invention relates to compounds of the formula wherein R1 to R4 are defined in the description, and to pharmaceutically acceptable salts thereof, their manufacture, pharmaceutical compositions containing them and their use as medicaments for the treatment and/or prophylaxis of diseases which can be treated with HDL-cholesterol raising agents, such as particularly dyslipidemia, atherosclerosis and cardiovascular diseases.
    Type: Grant
    Filed: September 11, 2012
    Date of Patent: January 14, 2014
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Uwe Grether, Stephan Roever
  • Pyrrolidine derivatives
    Patent number: 8524710
    Abstract: The invention relates to a compound of formula (I) wherein A1 to A4 and R1 to R6 are defined as in the description and in the claims. The compound of formula (I) can be used, for example, as inhibitors of the cysteine protease cathepsin.
    Type: Grant
    Filed: October 24, 2011
    Date of Patent: September 3, 2013
    Assignee: Hoffmann-La Roche Inc.
    Inventors: David Banner, Uwe Grether, Wolfgang Haap, Holger Kuehne, Harald Mauser, Jean-Marc Plancher
  • N-(5-cycloalkyl)-pyridin-3-yl carboxamides
    Patent number: 8455501
    Abstract: The present invention relates to compounds of the formula wherein R1 to R3 are defined in the description, and to pharmaceutically acceptable salts thereof, their manufacture, pharmaceutical compositions containing them and their use as medicaments for the treatment and/or prophylaxis of diseases which can be treated with HDL-cholesterol raising agents, such as particularly dyslipidemia, atherosclerosis and cardiovascular diseases.
    Type: Grant
    Filed: September 10, 2012
    Date of Patent: June 4, 2013
    Assignee: Hoffmann-La Roche Inc
    Inventors: Uwe Grether, Stephan Roever
  • -pyridin-3-yl or -pyrazin-2-yl carboxamides
    Patent number: 8410107
    Abstract: The present invention relates to compounds of formula I, wherein A, R1 to R7 are defined in the description, and to pharmaceutically acceptable salts thereof. The present invention also relates to the manufacture of such compounds or their pharmaceutically acceptable salts, pharmaceutical compositions containing them and their use as medicaments for the treatment and/or prophylaxis of diseases which can be treated with HDL-cholesterol raising agents, such as dyslipidemia, atherosclerosis and cardiovascular diseases.
    Type: Grant
    Filed: October 7, 2011
    Date of Patent: April 2, 2013
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Uwe Grether, Paul Hebeisen, Torsten Hoffmann, Stephan Roever
  • N-(5-CYCLOALKYL- OR 5-HETEROCYCLYL-)-PYRIDIN-3-YL CARBOXAMIDES
    Publication number: 20130065911
    Abstract: The present invention relates to compounds of the formula wherein R1 to R3 are defined in the description, and to pharmaceutically acceptable salts thereof, their manufacture, pharmaceutical compositions containing them and their use as medicaments for the treatment and/or prophylaxis of diseases which can be treated with HDL-cholesterol raising agents, such as particularly dyslipidemia, atherosclerosis and cardiovascular diseases.
    Type: Application
    Filed: September 10, 2012
    Publication date: March 14, 2013
    Inventors: Uwe Grether, Stephan Roever
  • 3-PYRIDINE CARBOXYLIC ACID HYDRAZIDES
    Publication number: 20130065876
    Abstract: The present invention relates to compounds of formula I, wherein R1 to R5 are defined in the description and claims, and to pharmaceutically acceptable salts thereof. The present invention relates also to the manufacture of said compounds, pharmaceutical compositions containing them and methods for the treatment and/or prophylaxis of diseases which can be treated with HDL-cholesterol raising agents, such as dyslipidemia, atherosclerosis and cardiovascular diseases.
    Type: Application
    Filed: September 11, 2012
    Publication date: March 14, 2013
    Inventors: Uwe Grether, Paul Hebeisen, Peter Mohr, Fabienne Ricklin, Stephan Roever
  • 5-CYCLOALKYL- OR 5-HETEROCYCLYL-NICOTINAMIDES
    Publication number: 20130065907
    Abstract: The present invention relates to compounds of the formula wherein R1 to R4 are defined in the description, and to pharmaceutically acceptable salts thereof, their manufacture, pharmaceutical compositions containing them and their use as medicaments for the treatment and/or prophylaxis of diseases which can be treated with HDL-cholesterol raising agents, such as particularly dyslipidemia, atherosclerosis and cardiovascular diseases.
    Type: Application
    Filed: September 11, 2012
    Publication date: March 14, 2013
    Inventors: Stephan Roever, Uwe Grether
  • NOVEL PYRIDINE DERIVATIVES
    Publication number: 20120316147
    Abstract: The invention relates to a compound of formula (I) wherein R1 to R4 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: June 1, 2012
    Publication date: December 13, 2012
    Inventors: Caterina Bissantz, Uwe Grether, Paul Hebeisen, Atsushi Kimbara, Qingping Liu, Matthias Nettekoven, Marco Prunotto, Stephan Roever, Mark Rogers-Evans, Tanja Schulz-Gasch, Christoph Ullmer, Zhiwei Wang, Wulun Yang